Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468466 | 0.83 | ATM (0.32) | SLC22A1ATMMEN1KMT2APOLB | |
| SCHEMBL38663307 | 0.79 | SMN1; SMN2 (0.32) | SLC22A1ATM | |
| SCHEMBL24471638 | 0.75 | — | — | |
| SCHEMBL24471478 | 0.71 | SMN1; SMN2 (0.37) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL1006687 | 0.71 | MAPT (0.32) | SLC22A1ALDH1A1ATMMEN1KMT2A | |
| SCHEMBL20465370 | 0.70 | ATM (0.33) | ALDH1A1ATMMEN1KMT2APOLB | |
| SCHEMBL14968076 | 0.68 | ALDH1A1 (0.34) | ALDH1A1ALOX15ATMPOLB | |
| SCHEMBL5718172 | 0.68 | MEN1 (0.34) | SLC22A1ALDH1A1ATMMEN1KMT2A | |
| SCHEMBL6785191 | 0.68 | MEN1 (0.34) | SLC22A1ALDH1A1ATMMEN1KMT2A | |
| SCHEMBL27131043 | 0.67 | GAA (0.36) | ALDH1A1ALOX15ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SLC22A1 4136/4885USP2 736/4885ALDH1A1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.